摘要
丙型肝炎病毒(HCV)感染的治疗已经有了显著的进展。从耐受性较差的注射治疗治疗率很低,转变为高度有效的耐受良好的口服直接作用的抗病毒疗法,几乎90%的患者得到了治愈。通过识别可被小分子抑制的靶点,直接抗病毒已经被发展为更进一步的理解病毒生命周期。目前为止,已经开发出了蛋白酶抑制剂,非结构性5a抑制剂以及核苷酸和非核苷酸聚合酶抑制剂。这些制剂最初被用于聚乙二醇化干扰素和利巴韦林,并且随后结合不需要使用干扰素。合理的联合用药已经克服了耐药性快速出现的主要挑战,而且每一类第二代药剂均具有改善的安全性和功效特性,药物相互作用较少,副作用很少。本文讨论了直接抗病毒的发展进展以及药物每一级以及将来发展所具有的挑战。
关键词: 直接抗病毒,耐药性,硬化,难治疗,丙型肝炎病毒
Current Drug Targets
Title:Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues
Volume: 18 Issue: 7
关键词: 直接抗病毒,耐药性,硬化,难治疗,丙型肝炎病毒
摘要: Treatment for hepatitis C virus (HCV) infection has progressed at remarkable speed. From poorly tolerated injectable therapy with very low cure rates, treatment has moved to highly effective well-tolerated all oral direct-acting antiviral therapies with cure rates above 90% for almost all patients populations. Direct-acting antivirals have developed out of an improved understanding of the viral lifecycle with recognition of targets that could be inhibited by small molecules. To date protease inhibitors, non-structural 5a inhibitors and nucleotide and non-nucleotide polymerase inhibitors have been developed. These agents have been used initially with peginterferon and ribavirin and subsequently in combination without the need for interferon. Rational combinations have overcome the major challenge of rapid emergence of drug resistance and second-generation agents in each class have improved safety and efficacy profiles with fewer drug-drug interactions and very few adverse effects. The progress of direct-acting antiviral development is outlined with a review of each class of agent as well as a discussion of challenges for the future.
Export Options
About this article
Cite this article as:
Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues, Current Drug Targets 2017; 18 (7) . https://dx.doi.org/10.2174/1389450116666150825111314
DOI https://dx.doi.org/10.2174/1389450116666150825111314 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Strategies Targeting DNA Topoisomerase I in Cancer Chemotherapy: Camptothecins, Nanocarriers for Camptothecins, Organic Non-Camptothecin Compounds and Metal Complexes
Current Drug Targets Fibrinogen Alpha Chain Acts as a HBsAg Binding Protein and their Interaction Promotes HepG2 Cell Apoptosis
Current Proteomics Editorial Review of 2012
Current Radiopharmaceuticals The Offer of Chemistry to Targeted Therapy in Cancer
Recent Patents on Biotechnology Curcumin: A Promising Agent Targeting Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Current Cardiology Reviews Carbon Nanotubes: An Emerging Drug Delivery Carrier in Cancer Therapeutics
Current Drug Delivery Recent Advances in Superparamagnetic Iron Oxide Nanoparticles for Cellular Imaging and Targeted Therapy Research
Current Pharmaceutical Design Chemical Genomic and Proteomic Methods for Determining Kinase Inhibitor Selectivity
Combinatorial Chemistry & High Throughput Screening Evolving Strategies for the Treatment of T-Cell Lymphoma: A Systematic Review and Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives
Current Medicinal Chemistry Design of New Oxazaphosphorine Anticancer Drugs
Current Pharmaceutical Design Recent Clinical Trials of Cladribine in Hematological Malignancies and Autoimmune Disorders
Reviews on Recent Clinical Trials Ginkgolic Acids Confer Potential Anticancer Effects by Targeting Pro- Inflammatory and Oncogenic Signaling Molecules
Current Molecular Pharmacology Multidrug Resistance Through the Spectacle of P-Glycoprotein
Current Cancer Drug Targets Structure-based Virtual Screening Approaches in Kinase-directed Drug Discovery
Current Topics in Medicinal Chemistry Aurora A and B Kinases - Targets of Novel Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry TRP Channels and Cancer: New Targets for Diagnosis and Chemotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Styrene Maleic Acid Neocarzinostatin Treatment for Hepatocellular Carcinoma
Current Medicinal Chemistry - Anti-Cancer Agents